rosiglitazone has been researched along with dynorphins in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caboni, P; Carboni, E; Carta, AR; Frau, L; Garau, A; Ibba, M; Schintu, N | 1 |
| Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A | 1 |
2 other study(ies) available for rosiglitazone and dynorphins
| Article | Year |
|---|---|
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; CD11b Antigen; Chromatography, High Pressure Liquid; Chronic Disease; Disease Models, Animal; Dopamine; Drug Interactions; Dynorphins; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Globus Pallidus; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; PPAR gamma; Psychomotor Performance; RNA, Messenger; Rosiglitazone; Smell; Tandem Mass Spectrometry; Thiazolidinediones; Tyrosine 3-Monooxygenase | 2009 |
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; PPAR gamma; Rats, Sprague-Dawley; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2015 |